ATE212040T1 - Herstellung von vernetzter amylose als hilfstoff zur kontrollierten freisetzung von wirkstoffen - Google Patents

Herstellung von vernetzter amylose als hilfstoff zur kontrollierten freisetzung von wirkstoffen

Info

Publication number
ATE212040T1
ATE212040T1 AT98902905T AT98902905T ATE212040T1 AT E212040 T1 ATE212040 T1 AT E212040T1 AT 98902905 T AT98902905 T AT 98902905T AT 98902905 T AT98902905 T AT 98902905T AT E212040 T1 ATE212040 T1 AT E212040T1
Authority
AT
Austria
Prior art keywords
cross
linked
high amylose
amylose starch
reaction medium
Prior art date
Application number
AT98902905T
Other languages
English (en)
Inventor
Yves Dumoulin
Francois Carriere
Andre Ingenito
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Application granted granted Critical
Publication of ATE212040T1 publication Critical patent/ATE212040T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
AT98902905T 1997-02-14 1998-02-10 Herstellung von vernetzter amylose als hilfstoff zur kontrollierten freisetzung von wirkstoffen ATE212040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/800,518 US5807575A (en) 1997-02-14 1997-02-14 Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
PCT/CA1998/000106 WO1998035992A1 (en) 1997-02-14 1998-02-10 Manufacture of cross-linked amylose useful as an excipient for control release of active compounds

Publications (1)

Publication Number Publication Date
ATE212040T1 true ATE212040T1 (de) 2002-02-15

Family

ID=25178603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98902905T ATE212040T1 (de) 1997-02-14 1998-02-10 Herstellung von vernetzter amylose als hilfstoff zur kontrollierten freisetzung von wirkstoffen

Country Status (12)

Country Link
US (1) US5807575A (de)
EP (1) EP0960131B1 (de)
AT (1) ATE212040T1 (de)
AU (1) AU726272B2 (de)
CA (1) CA2280534C (de)
DE (1) DE69803159T2 (de)
DK (1) DK0960131T3 (de)
ES (1) ES2171008T3 (de)
IL (1) IL131369A (de)
NZ (1) NZ337171A (de)
PT (1) PT960131E (de)
WO (1) WO1998035992A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
CA2423712A1 (en) 2003-03-26 2004-09-26 Nicolas Nourry Crosslinked amylopectin by reactive extrusion and its use as an absorbent or superabsorbent material
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
NZ539900A (en) * 2002-11-07 2008-03-28 Advanced Bionutrition Corp Nutraceuticals and method of feeding aquatic animals
US6846497B2 (en) * 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
EP1812025B1 (de) 2004-11-02 2012-09-05 Chr. Hansen A/S Stabilisierte bakteriophagen-formulierungen
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
WO2007048219A2 (en) 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
JP5122436B2 (ja) * 2006-03-14 2013-01-16 国立大学法人 奈良先端科学技術大学院大学 新規なヘパリン代替材料およびその製造方法
JP5453280B2 (ja) * 2007-10-16 2014-03-26 ラボファーム インコーポレイテッド アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
PT2234607E (pt) 2007-12-28 2011-09-30 Acraf Formulação de libertação lenta com base numa associação de glicogénio e alginato
RS53866B1 (sr) 2008-07-16 2015-08-31 Richter Gedeon Nyrt. Farmaceutske formulacije koje sadrže ligande dopaminskih receptora
CA2737247C (en) * 2008-09-15 2016-10-11 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
SG196810A1 (en) 2009-01-23 2014-02-13 Acraf Controlled release pharmaceutical or foodformulation and process for its preparation
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
US4667590A (en) * 1984-12-10 1987-05-26 Mars, Inc. Closed food processing system and liquid adjustment apparatus for use therein
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
ATE137668T1 (de) * 1992-07-24 1996-05-15 Labopharm Inc Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung

Also Published As

Publication number Publication date
IL131369A0 (en) 2001-01-28
PT960131E (pt) 2002-06-28
US5807575A (en) 1998-09-15
NZ337171A (en) 2000-09-29
WO1998035992A1 (en) 1998-08-20
DE69803159D1 (de) 2002-02-21
CA2280534C (en) 2003-08-19
EP0960131A1 (de) 1999-12-01
AU5978598A (en) 1998-09-08
AU726272B2 (en) 2000-11-02
DE69803159T2 (de) 2002-08-29
ES2171008T3 (es) 2002-08-16
IL131369A (en) 2002-12-01
DK0960131T3 (da) 2002-05-06
EP0960131B1 (de) 2002-01-16
CA2280534A1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
ATE212040T1 (de) Herstellung von vernetzter amylose als hilfstoff zur kontrollierten freisetzung von wirkstoffen
WO2002002084A8 (en) Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
ES2041885T3 (es) Un procedimiento para la fabricacion de un producto gelificado.
JPH0531000A (ja) 天然又は合成高分子化合物の選択的加水分解及び／又は熱分解方法
KR900701806A (ko) 올리고 -및/또는 폴리사카리드로 부터 얻은 알킬글루코시드 화합물의 제조방법
PL358378A1 (en) Process for cooking/drying high-amylose starches
MX9706062A (es) FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
ATE65940T1 (de) Kontinuierliches verfahren zur herstellung von natriumperborat-granulaten.
WO1999009066B1 (en) Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
NO976096L (no) FremgangsmÕte for fremstilling av por°se granuler og anlegg for utf°relse av fremgangsmÕten
ATE16271T1 (de) Zeolithgranulat, verfahren zu seiner herstellung und verwendung.
ATE154754T1 (de) Verfahren zur herstellung von pvp-h202-produkten
US20020132309A1 (en) Enzamatically modified hydrophobic starch
DE69306818D1 (de) Verfahren zur Herstellung von destrukturierter Stärke
MXPA99008569A (es) Polimerizacion de mono y disacaridos utilizando bajos niveles de acidos policarboxilicos.
BR0211841A (pt) Secagem de artigos cerâmicos durante manufatura
EP0261926A3 (de) Wärmeisoliermaterial und Verfahren zu seiner Herstellung
KR20030066076A (ko) 변성전분의 제조방법
DE50209196D1 (de) Verfahren zur herstellung von bleichaktivatorgranulaten
JPS55145532A (en) Treatment of used catalyst
KR950011475A (ko) 사이클로덱스트린의 제조방법
JPS6113486B2 (de)
KR100461565B1 (ko) 저점도 히드록시프로필메틸 셀룰로오스의 제조방법
TH20000A (th) แป้งและผงแป้งที่ใด้ยับยั้งแล้งด้วยความร้อน และขบวนการสำหรับการผลิต
TH25111B (th) แป้งและผงแป้งที่ใด้ยับยั้งแล้งด้วยความร้อน และขบวนการสำหรับการผลิต

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee